05:41 PM EDT, 08/06/2025 (MT Newswires) -- Revolution Medicines ( RVMD ) reported a Q2 loss late Wednesday of $1.31 per diluted share, widening from the loss of $0.81 a year earlier.

Analysts polled by FactSet expected a loss of $1.12.

As of June 30, the company had cash, cash equivalents and marketable securities of $2.14 billion.

The company expects a 2025 net loss of $1.03 billion to $1.09 billion, compared with the previous forecast for a loss of $840 million to $900 million.

Analysts polled by FactSet projected a loss of $883.8 million.